DJO enters $1.6bn merger agreement with ReAble
This article was originally published in Clinica
Musculoskeletal and vascular health specialist DJO is set to enter the folds of private equity, after agreeing to be acquired by the Blackstone Group's ReAble Therapeutics in a transaction worth approximately $1.6bn.
You may also be interested in...
Germany has ramped up its COVID-19 testing capacity to 260,000 per week, and still has a relatively low death rate from the virus. The country's diagnostics industry says it is ready to play its part “24/7.”
Health-system pharmacist organization assesses the evidence behind off-label use of existing drugs for COVID-19, along with top investigational prospects like Gilead’s remdesivir.
As American auto giants GM and Ford take the wheel on working with ventilator manufacturers to make the critically needed devices during the COVID-19 pandemic, two longtime quality experts explain where the device and auto companies will find common ground when it comes to quality systems.